Umecrine Cognition, a Karolinska Development portfolio company, announced yesterday evening results from a phase IIa study in patients with idiopathic hypersomnia (n=10). Overall results reported good safety and pharmacokinetics. Furthermore, indications of efficacy parameters are subject for further evaluation. We take a cautious stance in our change of estimates until we learn about the future development with GR3027 in sleep disorders.